The Biomedical Advanced Research and Development Authority (BARDA) has awarded Selux Diagnostics $9.6 million to fund its development of a next-generation phenotyping (NGP) platform to treat superbug infections and combat antibiotic resistance. The $9.6 million is the third funding tranche the company has received from BARDA as part of the company’s milestone-based contract. BARDA has…